Pliant Therapeutics, Inc.:
Focused on developing novel therapies for treatment of fibrosis. Pliant has developed a portfolio of fully-owned development candidates focused on inhibiting the TGFb pathway through integrin inhibition. The company’s lead product candidate, PLN-74809 is an oral small-molecule dual selective inhibitor of αvß6 and αvß1 integrins that is being developed in idiopathic pulmonary fibrosis (IPF), and primary sclerosing cholangitis (PSC). Positive results of a Phase 1b clinical study of PLN-7480 showed to inhibit TGF-β activation by up to 70% in alveolar macrophages collected from healthy volunteers, in a dose- and exposure-dependent manner. The second program, PLN-1474, targets advanced/end-stage liver fibrosis, and is in IND enabling studies.
Rare Disease, Respiratory
260 Littlefield Avenue
South San Francisco, CA 94080
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Solebury Trout Management Access: SF 2020
San Francisco, CA, United States,
January 13 –
January 16, 2020